City of Hope Partners with ChromaDex
Researchers will focus on pterostilbene’s connection to breast, ovarian and uterine cancers.
City of Hope (Duarte, CA) will soon begin studying the effects of pterostilbene on the treatment of ovarian, uterine and breast cancer at its Beckman Research Institute. The comprehensive cancer research and treatment center has partnered with ChromaDex Corp. (Irvine, CA), who will supply its pTeroPure brand pterostilbene for use in preclinical in vitro and mouse model experiments designed to determine its potential therapeutic treatment benefits.
Past in vitro studies have suggested that pterostilbene, an antioxidant primarily found in blueberries, is inherently able to prevent the growth of several common cancer cell malignancies with negligible toxicity. According to ChromaDex, earlier studies have acknowledged pterostilbene’s pronounced bioavailability in comparison to other stilbene compounds, though its mechanisms of actions in humans still warrant further study.
“By providing materials to BRICOH for preclinical studies, we will learn more about the potential of pTeroPure's application in cancer,” commented Frank Jaksch, ChromaDex founder and CEO. “This relationship will complement our ongoing partnership with UC-Irvine, where we are supporting ongoing research on pTeroPure’s use for non-melanoma skin cancer.”
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.
